Retransplantation of marrow and hematopoietic stem cells from normal donors

  • John A. Hansen
  • Jerald P. Radich
  • Effie Petersdorf
  • Paul J. Martin
  • Claudio Anasetti
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 29)


Transplantation of marrow or hematopoietic stem cells (HSC) from a normal donor requires high-dose marrow ablative conditioning in order to achieve full and sustained engraftment [1]. Graft failure is an uncommon problem following transplantation of marrow from an HLA identical sibling, but occurs more frequently in recipients of marrow from an HLA incompatible donor [2]. Graft failure can have catastrophic consequences, and prolonged pancytopenia may place the patient at high risk of infection or hemorrhage. Although severe graft failure is often fatal, autologous recovery of hematopoiesis can occur in some patients. The absence of donor cells and presence of host lymphoid cells suggests rejection as the cause of graft failure. Severe graft failure refractory to treatment with hematopoietic growth factors is a primary indication for retransplantation. Retransplantation may also be necessitated by recurrence of hematological malignancy. Additional immune suppression is usually necessary before retransplantation, and patients are usually very sensitive to the toxicity of additional conditioning therapy, especially if the time interval after initial transplantation is short. The feasibility of retransplantation and the optimal method depend on the primary disease and the condition of the patient.


Hematopoietic Stem Cell Umbilical Cord Blood Graft Failure Conditioning Regimen Hematopoietic Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thomas E, Storb R, Clift RA et al. Bone marrow transplantation. N. Engl. J. Med. 1975; 292: 832–843.PubMedCrossRefGoogle Scholar
  2. 2.
    Anasetti C, Amos D, Beatty PG et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N. Engl. J. Med. 1989; 320: 197–204.PubMedCrossRefGoogle Scholar
  3. 3.
    Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood 1995; 89: 4226–4235.Google Scholar
  4. 4.
    Bensinger WI, Clift R, Martin P et al. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794–2800.PubMedGoogle Scholar
  5. 5.
    Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of apiastic anemia. An analysis of factors associated with graft rejection. N. Engl. J. Med. 1977; 296: 61–66.PubMedCrossRefGoogle Scholar
  6. 6.
    Petersdorf EW, Longton GM, Anasetti C et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997; 89: 1818–1823.PubMedGoogle Scholar
  7. 7.
    Rubinstein P, Carrier C, Adamson, et al. New York Blood Center’s program for unrelated placental/umbilical cord blood (PBC) transplantation: 243 transplant in the first 3 years. Blood 1996; 88: 557: 142a.Google Scholar
  8. 8.
    Fleischhauer K, Kernan NA, O’Reilly RJ, Dupont B, Yang SY. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N. Engl. J. Med. 1990; 323: 1818–1822.PubMedCrossRefGoogle Scholar
  9. 9.
    Martin PJ, Hansen JA, Torok-Storb B et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988; 3: 445–456.PubMedGoogle Scholar
  10. 10.
    Anasetti C, Hansen JA. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus. Sci. 1994; 15: 221–230.PubMedCrossRefGoogle Scholar
  11. 11.
    Martin PJ, Hansen JA, Buckner CD et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 1985; 66: 664–672.PubMedGoogle Scholar
  12. 12.
    Scharf S. PCR amplification of VNTRs. In: Innis MA, Gelfand DH, Sninshy JJ (eds.), PCR Strategies. San Diego, Academic Press, 1995.Google Scholar
  13. 13.
    Hall JM, Lingenfelter P, Adams SL, Lasser D, Hansen JA, Bean MA. Detection of maternal cells in human umbilical cord blood using fluorescence in situ hybridization. Blood 1995; 86: 2892–2832.Google Scholar
  14. 14.
    Buckner CD, Clift RA, Sanders JE et al. Marrow harvesting from normal donors. Blood 1984; 64: 630–634.PubMedGoogle Scholar
  15. 15.
    Anasetti C, Martin PJ, Storb R et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54: 844–851.PubMedCrossRefGoogle Scholar
  16. 16.
    Anasetti C, Martin PJ, Storb R, Hansen JA. Engraftment of allogeneic hematopoietic stem cells in patients conditioned only with anti-CD3 monoclonal antibody BC3 plus methylprednisolone. Blood 1994; 84: 980: 249a.Google Scholar
  17. 17.
    Radich JP, Sanders JE, Buckner CD et al. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation containing regimens. J. Clin. Oncol. 1993; 11: 304–313.PubMedGoogle Scholar
  18. 18.
    Weiden P, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N. Engl. J. Med. 1979; 300: 1068–1073.PubMedCrossRefGoogle Scholar
  19. 19.
    Horowtiz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1990; 75: 555–562.Google Scholar
  20. 20.
    Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation._A case report of a probable graft-versus-leukemia effect. Transplantation 1990; 50: 175–177.PubMedCrossRefGoogle Scholar
  21. 21.
    Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.PubMedGoogle Scholar
  22. 22.
    Drobyski WR, Keever Ca, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310–2318.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • John A. Hansen
  • Jerald P. Radich
  • Effie Petersdorf
  • Paul J. Martin
  • Claudio Anasetti

There are no affiliations available

Personalised recommendations